- Coordinator
- Vib Vzw, Belgium
- Runs
- 1 September 2026 to 29 February 2028
- Status
- Running
- EU funding
- €150k
- Total cost
- —
- Partners
- 1 organisations in 1 countries
- Type
- European Research Council grant
- Grant agreement
- 101335284
What the project is doing
In the project's own words, from its summary on CORDIS.
Recent studies have demonstrated that mRNA-based vaccines targeting neoantigens, in combination with immune checkpoint blockade, can elicit robust anti-tumour responses across multiple cancer types. These advances have propelled the cancer vaccine market towards a projected growth from $7 billion to $19 billion by 2033. Despite this promise, critical technological hurdles remain. Current antigen selection strategies rely heavily on computationally predicted neoantigens, yet the majority fail to elicit detectable immune responses.
Paradoxically, clinical evidence confirms that increasing the number of immunogenic tumour antigens per vaccine correlates with improved patient benefit. This underscores the urgent need for antigen repertoires that extend beyond mutation-derived neoantigens. Moreover, because neoantigens are patient-specific, current vaccines must be personalized, introducing substantial manufacturing costs and logistical complexity.
TWISTAR addresses these limitations by advancing a next-generation vaccination strategy that incorporates not only somatic mutations but also functionally validated, shared tumour antigens derived from the ‘dark’ genome, which represents a rich and largely untapped source of immunogenic targets. By analysing tumour biopsies from triple-negative breast cancer (TNBC) patients, we have identified 10 such ‘dark’ antigens.
In a co-development partnership with myNEO Therapeutics, we will now evaluate the immunogenicity of these shared antigens and assess how many TNBC patients are capable of mounting a T-cell response against them. If successful, these validated dark antigens will translate into an off-the-shelf vaccine that complements immune checkpoint blockade and reduces the recurrence risk of triple-negative breast cancer.
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Vib Vzw | Zwijnaarde - Gent | Belgium | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI